AZD1152 in Patients With Advanced Solid Malignancies-Study 3 | NCT00497679

Studies
AZD1152 in Patients With Advanced Solid Malignancies-Study 3

NCT00497679

Sponsor

AstraZeneca

Status

Terminated

Last Update Posted

May 14, 2009Estimated

Enrollment

45Estimated

Phase

Phase 1

Conditions

Solid Tumours

Interventions

AZD1152

Countries

United Kingdom

Protocol Section

Identification Module Status Module Sponsor/Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms/Interventions Module Outcomes Module Eligibility Module Contacts/Locations Module References Module IPD Sharing Statement Module

Results Section

Participant Flow Module Baseline Characteristics Module Outcome Measures Module Adverse Events Module More Info Module

Annotation Section

Annotation Module

Document Section

Large Document Module

Derived Section

Miscellaneous Info Module Condition Browse Module Intervention Browse Module

Protocol Section

Identification Module

NCT ID

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Version Holder

ID	Type	Description	Link
EudraCT: 2005-004244-31

Status Module

Record Verification Date

May 2009

Overall Recruitment Status or Expanded Access Status

Terminated

Last Known Status

Not provided

Delayed Posting

Not provided

Why Stopped

Study is now terminated due to technical difficulties with administration of study drug in this patient population with this schedule

Expanded Access Info

Start Date

Aug 2006

Primary Completion Date

Not provided

Completion Date

Jul 2007Actual

First Submitted Date

Jul 5, 2007

First Submission Date that Met QC Criteria

Jul 5, 2007

First Posted Date

Jul 9, 2007Estimated

Results Waived

Not provided

Results First Submitted Date

Not provided

Results First Submitted that Met QC Criteria

Not provided

Results First Posted Date

Not provided

Certification/Extension (aka Delayed Results) First Submitted Date

Not provided

Certification/Extension First Submitted that Passed QC Review

Not provided

Certification/Extension First Posted Date

Not provided

Last Update Submitted Date

May 13, 2009

Last Update Posted Date

May 14, 2009Estimated

Sponsor/Collaborators Module

Responsible Party, by Official Title

Not provided

Lead Sponsor

AstraZenecaINDUSTRY

Collaborators

Not provided

Oversight Module

Has Data Monitoring Committee (DMC)

Is FDA Regulated Drug

Not provided

Is FDA Regulated Device

Not provided

Is Unapproved Device

Not provided

Pediatric Postmarket Surveillance of a Device Product

Not provided

Product Exported from US

Not provided

FDAAA801 Violation

Not provided

Description Module

Brief Summary

The primary purpose of this protocol is to investigate the safety and tolerability of AZD1152 when given as a continuous 7-day infusion every week and every 2 weeks in patients with advanced solid malignancies.

Detailed Description

Not provided

Design Module

Study Type

Interventional

Number of References to an Expanded Access Study

Not provided

Expanded Access Types

Not provided

Patient Registry

Not provided

Target Follow-Up Duration

Not provided

Phases

Phase 1

Interventional Study Design

Allocation

Biospecimen

No data available

No data is available for this block.

Enrollment

45Estimated

Arms/Interventions Module

Arm Groups

Not provided

Interventions

Name	Type	Description	Arm Group Labels	Other Names
AZD1152	Drug	7-day continuous intravenous infusion

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Safety and Tolerability		Assessed at each visit

Secondary Outcomes

Measure	Description	Time Frame
Pharmacokinetics		Assessed at predetermined timepoints after dose administration
Effect on biomarkers		Assessed after treatment
Anti-tumor activity

Other Outcomes

Not provided

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

Histological or cytological confirmation of a solid, malignant tumour

Exclusion Criteria:

Participation in an investigational drug study within 21 days prior to entry or who have not recovered from the effects of an investigational study drug
Treatment with radiotherapy/chemotherapy with 4 weeks of first dose
Recent major surgery within 4 weeks prior to entry to the study

Accepts Healthy Volunteers

Sex

All

Sex/Gender Based

Not provided

Sex/Gender Description

Not provided

Minimum Age

18 Years

Maximum Age

Not provided

Standard Ages

AdultOlder Adult

Study Population

Not provided

Sampling Method

Not provided

Contacts/Locations Module

Central Contacts

Not provided

Overall Officials

Name	Affiliation	Role
David Kerr, MD	University of Oxford	Principal Investigator

Locations

Facility	Status	City	State	ZIP	Country	Contacts
Research Site		Manchester			United Kingdom
Research Site

Intervention Browse Module

MeSH Terms

ID	Term
C520647	2-((3-((4-((5-(2-((3-fluorophenyl)amino)-2-oxoethyl)-1H-pyrazol-3-yl)amino)quinazolin-7-yl)oxy)propyl)(ethyl)amino)ethyl dihydrogen phosphate

Ancestor Terms

Not provided

Browse Leaves

Not provided

Browse Branches

Not provided